Calls under review
Horizon Europe Health Cluster
Second stage of 2025 two-stage calls and one-stage 2026 calls are under evaluation.
The “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (MultiPMData2026)’ RITC call has two stages for applicants, both of which have now closed. Full proposals are currently under review with the rebuttal stage due to open at the end of June and overall outcome results expected in early September.
European Rare Diseases Research Alliance (ERDERA) Joint Transnational Call (JTC) 2026
‘Resolving unsolved cases in rare genetic and non-genetic diseases’ is the ERDERA JTC 2026 call topic. Pre-proposal submissions closed on 12 Feb 2026 and applicants have been informed of the peer review outcome with successful applicants invited to submit full proposals by 8 July 2026. Please ensure to submit required documentation to the HRB within the communicated timelines.
Open Calls
EU Cancer Mission 2026 – 2027
The EU Cancer Mission 2026-2027 Work Programme is now published. Watch the Cancer Mission 2026 Info Day here.
2026 Single Stage call is currently open and will close on 15th Sept 2026. There are 7 call topics open for submission:
HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease
HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (CSA)
HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
EU Partnerships
Why apply?
- Learn from leading international experts in personalised and gender-sensitive medicine
- Gain practical skills to improve prevention, diagnosis, and treatment strategies
- Explore cutting-edge topics including pharmacogenomics, immuno-oncology, AI bias and more…
- Strengthen your ability to design and implement gender-responsive healthcare solutions
- Network with a multidisciplinary group of professionals across Europe
Format: Hybrid (onsite and online participation available via invitation to successful applicants)
Dates: 27 – 30 October 2026
Location: Vilnius University Medical Centre, Lithuania
Applications Close: 01 June 2026 Apply Here
European Rare Disease Research Alliance (ERDERA) Networking Support Scheme
The Networking Support Scheme (NSS) is a continuously open call designed to knit together researchers, clinicians and patient advocates working on rare diseases and rare cancers. Proposals may be lodged at any time.
Under the scheme, applicants can request up to €30,000 per networking event to cover meeting costs, travel costs, hybrid-meeting platforms and other essentials. Rounds will be held every six months until April 2029 – or until the dedicated budget is exhausted – providing a response pathway for emerging collaborations of the partnership.
See our Grant updates story for information on Joint Transnational Calls funded through European Partnerships.
EDCTP3 2026 Work Programme
The Global Health EDCTP3 Work Programme 2026 is now published. Read to find opportunities for global health researchers.
Recording and presentations of the Global Health EDCTP3 Info Day 2026 and online networking can be found here.
One Stage Call: Full proposal deadline is 2 September 2026. Call topics include:
HORIZON-JU-GH-EDCTP3-2026-03-SERP-01: Training and innovation networks for sustained capacity development related to ethics, regulatory, pharmacovigilance, and related digital regulatory platforms
HORIZON-JU-GH-EDCTP3-2026-03-DIGIT-02: Enhancing integrated research and healthcare in sub-Saharan Africa through digital innovation and Artificial Intelligence.
Two-Stage Calls: Stage 1 submission deadline was 4 March 2026 and full proposal deadline is 17 September 2026.
Upcoming Calls
EU4Health
The EU4Health 2025 Work Programme closed its calls for proposals in January 2026. The new EU4Health 2026 Work Programme is expected to be published later this year, after which new calls for proposals will be launched.
EU4Health 2025 Work Programme upcoming calls for tender
HADEA/2026/OP/0015-PIN: Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures – Next Generation Therapeutics for Infectious Diseases. Publication date 27 May 2026; deadline 3 July 2026; indicative budget €244 million.
HADEA/2026/OP/0019-PIN: Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve. Publication date 1 June 2026; deadline 30 September 2026; indicative budget €16 million.
HADEA/2026/OP/0020-PIN: EU FAB+ Multiple Sourcing Pilot for Capacity Reservation for Personal Protective Equipment (PPE). Publication date 30 June 2026; deadline 10 September 2026; indicative budget €34 million.
Further calls for tenders are expected and will be published throughout in the year.
Horizon Europe Health Cluster 2026 – 2027
The Horizon Europe Health Cluster 2026-2027 Work Programme is now published.
2027 Horizon Europe funding opportunities for researchers include:
2027 Single Stage – set 1 of 2027 calls:
Open on 10 February 2027 and close on 13 April 2027.
HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change (PCP)
HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
2027 two-Stage calls – set 2 of 2027 calls
Currently, first stage opens 10 February 2027 and closes 13 April 2027, however timeline is under discussion and deadlines are expected to change, Second stage deadline is 22 September 2027.
HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
HORIZON-HLTH-2027-02-DISEASE-14- two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseases
HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable disease
HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics (IA)
2027 Single Stage calls – set 3 of 2027 calls
Calls open 3 June 2027 and close 22 Sept 2027.
HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
HORIZON-HLTH-2027-03-TOOL-08: Towards Artificial General Intelligence (AGI) for healthcare (CSA)
EU Cancer Mission 2026 – 2027
The EU Cancer Mission 2026-2027 Work Programme is now published.
2027 opportunities for cancer researchers include:
2027 Single Stage calls
Calls open 10 February 2027 and close 21 Sept 2027.
HORIZON-MISS-2027-02-CANCER-01: Leveraging functional genomics to reveal novel targets for cancer treatment
HORIZON-MISS-2027-02-CANCER-02: Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers (IA)
HORIZON-MISS-2027-02-CANCER-03: Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multimodal treatment interventions for patients with rare or very rare cancers or cancer subtypes
HORIZON-MISS-2027-02-CANCER-04: Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
HORIZON-MISS-2027-02-CANCER-05: Precommercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines (PCP)
HORIZON-MISS-2027-02-CANCER-06: Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
HORIZON-MISS-2027-06-SOIL-CANCER: Living labs to monitor and mitigate carcinogenic substances in and originating from soils: Evaluating their effects on human cancer risks
See also the HRB website for general information on the Horizon Europe and EU4Health programmes.
